CytRx Corporation (CYTR) has been under a strong bear grip, hence the stock is down -7.37% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 6.27% in the past 1 week. The stock has risen by 5.57% in the past week indicating that the buyers are active at lower levels, but the stock is down -7.57% in the past 4 weeks.
For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a twenty day Moving Average of 2.26% and the fifty day Moving Average is 49.69%. CytRx Corporation has dropped 78.39% during the last three month period . Year-to-Date the stock performance stands at -77.33%.
CytRx Corporation (CYTR) : Currently there are 3 street experts covering CytRx Corporation (CYTR) stock. The most bullish and bearish price target for the stock is $10 and $1 respectively for the short term. The average price target of all the analysts comes to $4.58. The estimated standard deviation from the target is $4.82.
CytRx Corporation (NASDAQ:CYTR): stock turned positive on Friday. Though the stock opened at $0.588, the bulls momentum made the stock top out at $0.614 level for the day. The stock recorded a low of $0.5805 and closed the trading day at $0.6008, in the green by 1.83%. The total traded volume for the day was 1,807,166. The stock had closed at $0.59 in the previous days trading.
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The company is focused on the clinical development of aldoxorubicin, its modified version of a chemotherapeutic agent. Aldoxorubicin is a conjugate of the commonly prescribed chemotherapeutic agent doxorubicin that binds to circulating albumin in the bloodstream and is concentrated at the site of tumors. It consists of (6-Maleimidocaproyl) hydrazine, an acid-sensitive molecule that is conjugated to doxorubicin. Its laboratory in Freiburg, Germany is conducting discovery and translational research to create drug candidates that utilize linker technologies that couple chemotherapeutic agents and proteins either inside the body or externally, and then concentrate drug in tumors.